Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
Status:
Recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with
locally advanced and resectable oral squamous cell carcinoma, and the CPS>10 in the biopsy
samples.